Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Mar 2;324(7336):520.
doi: 10.1136/bmj.324.7336.520.

Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial

G T Lewith  1 , A D Watkins, M E Hyland, S Shaw, J A Broomfield, G Dolan, S T Holgate
Affiliations
Clinical Trial

Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial

G T Lewith et al. BMJ. .

Abstract

Objective: To evaluate the efficacy of homoeopathic immunotherapy on lung function and respiratory symptoms in asthmatic people allergic to house dust mite.

Design: Double blind randomised controlled trial.

Setting: 38 general practices in Hampshire and Dorset.

Participants: 242 people with asthma and positive results to skin prick test for house dust mite; 202 completed clinic based assessments, and 186 completed diary based assessments.

Intervention: After a four week baseline assessment, participants were randomised to receive oral homoeopathic immunotherapy or placebo and then assessed over 16 weeks with three clinic visits and diary assessments every other week.

Outcome measure: Clinic based assessments: forced expiratory volume in one second (FEV(1)), quality of life, and mood. DIARY BASED ASSESSMENTS: morning and evening peak expiratory flow, visual analogue scale of severity of asthma, quality of life, and daily mood.

Results: There was no difference in most outcomes between placebo and homoeopathic immunotherapy. There was a different pattern of change over the trial for three of the diary assessments: morning peak expiratory flow (P=0.025), visual analogue scale (P=0.017), and mood (P=0.035). At week three there was significant deterioration for visual analogue scale (P=0.047) and mood (P=0.013) in the homoeopathic immunotherapy group compared with the placebo group. Any improvement in participants' asthma was independent of belief in complementary medicine.

Conclusion: Homoeopathic immunotherapy is not effective in the treatment of patients with asthma. The different patterns of change between homoeopathic immunotherapy and placebo over the course of the study are unexplained.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients entered, randomised, and withdrawn from trial
Figure 2
Figure 2
Variables measured at clinic visits (FEV1) and from diaries (asthma visual analogue score (VAS), peak expiratory flow (PEF), mood, symptoms, use of bronchodilator). Error bars for each graph are same because of method of analysis used. Baseline figures are averages of two recordings for each variable
See this image and copyright information in PMC

Comment in

Summary for patients in

References

    1. National Association of Health Authorities and Trusts. Complementary therapies in the NHS. Birmingham: NAHAT; 1993. (research paper 10).
    1. Fisher P, Ward A. Complementary medicine in Europe. BMJ. 1994;309:107–111. - PMC - PubMed
    1. Ernst E. Use of complementary therapies in childhood asthma. Pediatr Asthma Allergy Immunol. 1998;12:29–32.
    1. Letts M. The jury's out. National Asthma Campaign report. London: National Asthma Campaign; 1998.
    1. Eizayaga FX, Eizayage J, Eizayaga F. Homoeopathic treatment of bronchial asthma. Br Homeopath J. 1996;85:28–33.

Publication types